SSCIP Houses Haisco Pharmaceutical Corporation R&D and Marketing Headquarters

On October 21, Haisco Pharmaceutical Corporation (Haisco Pharmaceutical) won the bid for three pieces of land in Singapore-Sichuan High-Tech Innovation Park (SSCIP), announcing its entry in SSCIP.

Equipped with strong research and development capabilities, Haisco Pharmaceutical’s business covers generic drugs, small molecule chemical innovative drugs and monoclonal antibodies. It is a well-known pharmaceutical company with strong marketing and sales network across China. Haisco Pharmaceutical plans to establish a R&D and marketing headquarters in SSCIP, including R&D centers for generic drugs, original new drugs and monoclonal antibodies, as well as the group headquarters, a financial and administrative center, a marketing center and a training center. The total investment is expected to be around RMB 660 million.

The project is in line with the biomedical sciences industry positioning of SSCIP and it will establish a translational platform through enterprise R&D and training. Haisco Pharmaceutical also has strong partnerships with many major pharmaceutical enterprises and hospitals globally. Haisco Pharmaceutical invested in SSCIP will great balance the biomedical ecosystem of SSCIP.

Location: the fourth cluster in SSCIP mainly planned for the development of biomedical sciences industry.

About Haisco Pharmaceutical Corporation

Haisco Pharmaceutical Corporation (Haisco Pharmaceutical), founded in 2000, is a public listed company focusing on R&D of therapeutic new drugs. Haisco Pharmaceutical has outstanding capability of marketing and sales. So far, Haisco Pharmaceutical was ranked top 3 among all listed chemical and chemistry drug manufacturer companies. It was also listed No.3 in the Forbes Top 100 Most Potential Chinese Listed Enterprises Year of 2014; No.1 in the group of medical and pharmaceutical enterprises.

Haisco Pharmaceutical is strong in their technologies, with its R&D centers consisting of 450 research specialists. Many of them are PhD and Master’s degrees holders. Currently, the work of R&D centers focus on various clinic treatment areas, such as parenteral nutrition, tumors, cardiovascular diseases, endocrine and nervus centralis. The centers have already launched 60 new R&D projects.